Nature Biotechnology

doi: 10.1038/nbt0305-267pmid: 15765066

Ratner, Mark

doi: 10.1038/nbt0305-269pmid: 15765067

The ability of biotech companies to efficiently use financial and commercial resources reflects their maturity.

Herrera, Stephan

doi: 10.1038/nbt0305-270pmid: 15765068

Industrial applications of synthetic biology as not as closeby as the media buzz makes us believe.

Sheridan, Cormac; Katsnelson, Alla

doi: 10.1038/nbt0305-272pmid: 15765069

Reimbursement agencies are increasingly likely to require some economic data to back the claims on the superior value of biotech drugs compared to traditional ones.

Fox, Jeffrey L.

doi: 10.1038/nbt0305-274pmid: 15765070

A new rule preventing NIH scientists from any outside employment by private organizations may not have such a negative effect on the biotech industry.

Sipp, Doug

doi: 10.1038/nbt0305-275pmid: 15765071

Japanese corporations in seemingly unrelated areas such as automobile or electronics sector, are now investing in areas of life science such as industrial biotechnology that could contribute to applications enhancing their existing products.

doi: 10.1038/nbt0305-277pmid: N/A

Herrera, Stephan

doi: 10.1038/nbt0305-280pmid: 15765073

Ex-Greenpeace activist turned biotech supporter believes that auditing the performance of biotech products is the only way to convince people of their value.

Lawrence, Stacy

doi: 10.1038/nbt0305-281pmid: 15765074

Dove, Alan W

doi: 10.1038/nbt0305-283pmid: 15765075

Biotech animals don't have the market value of biotech drugs and potential controversies loom large, but genetic screening technologies are already finding a market, and both cloned and transgenic animals may soon be on the menu. Alan Dove reports.